Changeflow GovPing Pharma & Drug Safety Method for Preparing Polydopamine Nanomotor Usi...
Routine Rule Added Final

Method for Preparing Polydopamine Nanomotor Using Urease and Use of Same

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

USPTO granted Patent US12599571B2 to POSTECH Research and Business Development Foundation for a biocompatible polydopamine nanomotor using urease. The nanomotor is designed to infiltrate bladder walls in biological environments and remain inside the bladder for extended periods. The patent includes 10 claims covering the preparation method and therapeutic applications.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO issued Patent US12599571B2 to POSTECH Research and Business Development Foundation covering a method for preparing polydopamine nanomotors using urease and their use for bladder infiltration. The invention relates to biocompatible nanomotors capable of penetrating bladder walls and sustained residence within the bladder for therapeutic delivery.

For affected parties, this patent grant establishes exclusive rights for POSTECH in the United States for the claimed nanomotor technology and methods. Competitors developing similar urease-powered polydopamine nanomotors for bladder therapy or anticancer applications may need to design around these claims or seek licensing arrangements.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Method for preparing polydopamine nanomotor using urease, and use of same

Grant US12599571B2 Kind: B2 Apr 14, 2026

Assignee

POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION

Inventors

Sei Kwang Hahn, Hyun Sik Choi, Sang Baie Shin

Abstract

The present invention relates to a biocompatible polydopamine nanomotor capable of infiltrating a bladder wall in a biological environment and remaining inside a bladder for a long time.

CPC Classifications

A61K 9/51 A61K 45/06 A61K 47/18 A61K 47/69 A61K 9/5138 A61K 31/00 A61K 47/6925 A61P 13/10 A61P 35/00 B82Y 5/00

Filing Date

2020-03-10

Application No.

17905821

Claims

10

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12599571B2

Who this affects

Applies to
Pharmaceutical companies Medical device makers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Therapeutic nanomotor technology
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!